PRECLINICAL SAFETY AND IMMUNOGENICITY OF GROUP B MENINGOCOCCAL VACCINES
B 组脑膜炎球菌疫苗的临床前安全性和免疫原性
基本信息
- 批准号:5200675
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:Macaca mulatta Neisseria meningitidis Neisseria meningitidis vaccine active immunization antibacterial antibody antibody formation antibody specificity bacterial antigens bacterial capsules bacterial polysaccharides bactericidal immunity drug screening /evaluation enzyme linked immunosorbent assay humoral immunity immunoconjugates nonhuman therapy evaluation serum albumin
项目摘要
The binding specificity of rhesus antibodies elicited by various
conjugate vaccines of group B Neisseria meningitidis (GBNM) was studied
using a variety of group B meningococcal polysaccharide (GBPS) antigen
systems. The antibody response, as measured by ELISA, was significantly
higher to the spacer-containing GBPS or N-propionylated version of GBPS
than to the native GBPS complexed with methylated human serum albumin
(HSA). The specificity of a population of antibodies directed to the
spacer, ADH, was confirmed by their binding to an unrelated pneumococcal
9V polysaccharide conjugated to HSA through ADH. Antibodies elicited by
GBPS-OMV conjugate vaccine also showed binding to N-propionylated GBPS
conjugated to HSA. Pooled sera of high responders from various vaccine
groups showed varied degree of opsonophagocytic activity in presence of
monkey complement.
As an extension of the previous immunization schedule, four groups of
monkeys were further immunized first with the purified GBPS alone at week
50 and then with killed whole cell vaccine of GBNM at week 72. While the
booster immunization with pure GBPS did not increase the capsular
antibody levels significantly, immunization with killed cells produced
antibodies to the whole cell antigen.
Neither multiple immunizations with the conjugates nor reimmunization
with GBPS or killed whole cell vaccine resulted in any discernible
safety-related symptoms in the monkeys.
结合特异性的恒河猴抗体由各种
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
S DEVI其他文献
S DEVI的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('S DEVI', 18)}}的其他基金
TRICHOSPORON BIEGELII PS CROSS REACTS WITH CRYPTOCOCCAL CAPSULAR ANTIGEN
Trichosporon BIEGELII PS 与隐球菌荚膜抗原发生交叉反应
- 批准号:
3748115 - 财政年份:
- 资助金额:
-- - 项目类别:
CAPSULAR POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES OF VIBRIO VULNIFICUS
创伤弧菌荚膜多糖-蛋白结合疫苗
- 批准号:
3748114 - 财政年份:
- 资助金额:
-- - 项目类别:
IMMUNE RESPONSE TO GROUP B MENINGOCOCCAL CAPSULAR POLYSACCHARIDE
对 B 组脑膜炎球菌荚膜多糖的免疫反应
- 批准号:
3748105 - 财政年份:
- 资助金额:
-- - 项目类别:
IMMUNE RESPONSE TO GROUP B MENINGOCOCCAL POLYSACCHARIDE
对 B 组脑膜炎球菌多糖的免疫反应
- 批准号:
3792319 - 财政年份:
- 资助金额:
-- - 项目类别:
CAPSULAR POLYSACCHARIDE-PROTEIN CONJUGATE VACCINES OF VIBRIO VULNIFICUS
创伤弧菌荚膜多糖-蛋白结合疫苗
- 批准号:
5200680 - 财政年份:
- 资助金额:
-- - 项目类别:
TRICHOSPORON BIEGELII PS CROSS REACTS WITH CRYPTOCOCCAL CAPSULAR ANTIGEN
Trichosporon BIEGELII PS 与隐球菌荚膜抗原发生交叉反应
- 批准号:
5200681 - 财政年份:
- 资助金额:
-- - 项目类别:
PRECLINICAL SAFETY AND IMMUNOGENICITY OF GROUP B MENINGOCOCCAL VACCINES
B 组脑膜炎球菌疫苗的临床前安全性和免疫原性
- 批准号:
2568873 - 财政年份:
- 资助金额:
-- - 项目类别:
IMMUNE RESPONSE TO GROUP B MENINGOCOCCAL CAPSULAR POLYSACCHARIDE
对 B 组脑膜炎球菌荚膜多糖的免疫反应
- 批准号:
3770275 - 财政年份:
- 资助金额:
-- - 项目类别:
相似海外基金
Molecular mechanisms underlying glial inflammatory responses to Neisseria meningitidis: A pilot study
神经胶质细胞对脑膜炎奈瑟菌炎症反应的分子机制:一项初步研究
- 批准号:
10452116 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Molecular mechanisms underlying glial inflammatory responses to Neisseria meningitidis: A pilot study
神经胶质细胞对脑膜炎奈瑟菌炎症反应的分子机制:一项初步研究
- 批准号:
10551245 - 财政年份:2022
- 资助金额:
-- - 项目类别:
Identification of bactericidal antibody specificities for the development of novel broad-coverage vaccine candidates against Neisseria meningitidis
鉴定杀菌抗体特异性,用于开发针对脑膜炎奈瑟菌的新型广泛覆盖候选疫苗
- 批准号:
10404598 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Acquisition of gonococcal denitrification apparatus in the Neisseria meningitidis urethritis clade
脑膜炎奈瑟菌尿道炎分支中淋菌反硝化装置的获得
- 批准号:
10317302 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Acquisition of gonococcal denitrification apparatus in the Neisseria meningitidis urethritis clade
脑膜炎奈瑟菌尿道炎分支中淋菌反硝化装置的获得
- 批准号:
10448441 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Identification of bactericidal antibody specificities for the development of novel broad-coverage vaccine candidates against Neisseria meningitidis
鉴定杀菌抗体特异性,用于开发针对脑膜炎奈瑟菌的新型广泛覆盖候选疫苗
- 批准号:
10256250 - 财政年份:2021
- 资助金额:
-- - 项目类别:
Defining the link between viral co-infection and the invasive potential of Neisseria meningitidis
确定病毒合并感染与脑膜炎奈瑟菌侵袭潜力之间的联系
- 批准号:
449574 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Studentship Programs
Antimicrobial susceptibility and penicillin resistance mechanism in the Japanese clinical isolates of Neisseria meningitidis
日本临床分离脑膜炎奈瑟菌的耐药性及青霉素耐药机制
- 批准号:
20K08818 - 财政年份:2020
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Revealing processes that confer immunity against nasal colonization by Neisseria meningitidis
揭示赋予脑膜炎奈瑟菌鼻定植免疫力的过程
- 批准号:
408154 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Studentship Programs
The CRISPR/Cas system in Neisseria meningitidis and its potential role in host cell adhesion
脑膜炎奈瑟菌中的CRISPR/Cas系统及其在宿主细胞粘附中的潜在作用
- 批准号:
405974664 - 财政年份:2018
- 资助金额:
-- - 项目类别:
Priority Programmes